Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04180774
Other study ID # 07-???-?
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date January 31, 2001
Est. completion date December 31, 2018

Study information

Verified date November 2019
Source N.N. Petrov National Medical Research Center of Oncology
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study was designed to assess the safety and efficacy of inactivated tumor cells genetically modified with the TAG-7 gene as immunotherapy for cancer. Patients with melanoma or kidney cancer were included since they have immune-dependent tumors. Treatment was done in the adjuvant setting after complete cytoreduction of locally advanced or metastatic disease or in the therapeutic setting in patients where complete cytoreduction was impossible.


Description:

During the last decade, novel approaches for cancer treatment have been developed. Antitumor vaccines are one of the most promising approaches in tumor immunotherapy. Tumor cells possess low immunogenicity properties due to a number of the not completely understood mechanisms of resistance. One of the ways to overcome it is immune genes transfection. Genes encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-2 and IL-12 have been used most commonly, both in preclinical studies and clinical trials. These cytokines are well known to participate in the systemic immune response. Several studies have shown that the professional antigen-presenting cells (APCs) of the host, rather than the vaccinating tumor cells themselves, are responsible for priming CD4+ and CD8+ T cells, both of which are required to generate systemic antitumor immunity. Recent findings indicate that the adaptive arm of immunity is governed by the innate immune mechanisms that control the co-stimulatory signaling of APCs. Recently, investigators identified a novel gene, tag7, also know as PGRP-S. The insect ortholog of the tag7/PGRP-S was shown to be involved in the innate immune response in Drosophila. In preclinical studies, tag7-modified mouse tumor cells induced a long-lasting T-cell dependent immune response in mice. The effectiveness of antitumor vaccination was demonstrated on different models of mouse tumors, particularly for melanoma cells (M3, B16, F10). Clinically important results of vaccine therapy were achieved in patients with melanoma and renal carcinoma in a number of studies. The results with this treatment are comparable to chemotherapy and immunotherapy. Investigators assume that one has to activate the innate component of immunity first, followed by the activation of the adaptive one, to make anticancer vaccines more effective. Thus, a phase I/II clinical trial has been performed to evaluate the feasibility and toxicity of treatment with autologous tumor cells modified with the tag7 gene, which has been shown to be involved in innate immunity mechanisms,


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date December 31, 2018
Est. primary completion date December 31, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Signed inform consent form.

2. Patients age = 18 years of age at the time of informed consent.

3. Ability to provide and understand written informed consent prior to any study procedures.

4. Histologically confirmed locally advanced or metastatic MM or RCC.

5. Tumor cell culture should be obtained and successfully transfected before inclusion.

6. No evaluable therapy with a proved survival advantage in the current patient setting.

7. The life expectancy of > 3 months as estimated by the investigator

8. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 -2 at Screening.

Exclusion Criteria:

1. Patient with any out-of-range laboratory values defined as:

- Serum creatinine > 1.5 × upper limit of normal (ULN) and/or creatinine clearance (calculated using Cockcroft-Gault formula, or measured) < 50 mL/minute

- Total bilirubin > 2.5 × ULN, except for patients with Gilbert's syndrome who are excluded if total bilirubin > 3.0 × ULN or direct bilirubin > 1.5 × ULN

- Alanine aminotransferase > 2.5 × ULN

- Aspartate aminotransferase > 2.5 × ULN

- Absolute neutrophil count < 1.5 × 109/L

- Platelet count < 100 × 109/L

- Hemoglobin < 80 g/L (blood transfusions permitted)

2. History of severe hypersensitivity reactions (eg, anaphylaxis) to other biologic drugs or monoclonal antibodies

3. Any clinically significant unstable disease

4. Presence of symptomatic or untreated central nervous system (CNS) metastases

5. Active infection requiring systemic antibiotic therapy. Patients requiring systemic antibiotics for infection must have completed therapy at least 1 week prior to the first dose of study drug

6. Known history of human immunodeficiency virus infection (HIV). Testing for HIV status is not necessary unless clinically indicated

7. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection per institutional protocol. Testing for HBV or HCV status is not necessary unless clinically indicated or the patient has a history of HBV or HCV infection

8. Malignant disease, other than that being treated in this study

9. Patients receiving systemic steroid therapy or any other systemic immunosuppressive medication at any dose level, as these may interfere with the mechanism of action of study treatment. Local steroid therapies (eg, otic, ophthalmic, intra-articular or inhaled medications) are acceptable

10. Pregnant, likely to become pregnant, or lactating women (where pregnancy is defined as the state of a female after conception and until the termination of gestation)

Study Design


Intervention

Biological:
Tag-7 gene modified inactivated tumor cells
Patients received GMV once in three weeks subcutaneously in three points in the paravertebral region. One dose consisted of 10 million transfected and inactivated tumor cells. No dose reduction was allowed.

Locations

Country Name City State
Russian Federation N.N. Petrov Research Institute of Oncology Chemotherapy and Innovative Technologies Department St. Petersburg

Sponsors (2)

Lead Sponsor Collaborator
N.N. Petrov National Medical Research Center of Oncology Institute of Gene Biology Russian Academy of Sciences

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse events rate CTC AE v.3 was used for safety assesment From the fist injection to 3 month after the last injection
Secondary Response rate To assess the objective response rate (OR) RECIST v1.1 and irRC were used at the final assesment every 8 weeks until disease progression or therapy completion, then every 3 month for 2 years, every 6 month for the next 2 years and annually thereafter
Secondary Concentration of MICA in patient's cultures supernatants Factor production by culture of patient's tumor cells, used for vaccine preparation Samples obtained before therapy start
Secondary Concentration of TGF-ß1 in patient's cultures supernatants Factor production by culture of patient's tumor cells, used for vaccine preparation Samples obtained before therapy start
Secondary Concentration of IL-10 in patient's cultures supernatants Factor production by culture of patient's tumor cells, used for vaccine preparation Samples obtained before therapy start
Secondary Concentration of VEGF in patient's cultures supernatants Factor production by culture of patient's tumor cells, used for vaccine preparation Samples obtained before therapy start
Secondary Number of T-cells in peripheral blood of patients Absolute (10^9/L) of CD3+ cells in peripheral blood 1-5 days before each therapy cycle during course of therapy (cycle 21 days) through therapy completion, an average of 6 cycles (18 weeks)
Secondary Number of T-helper lympocytes in peripheral blood of patients Absolute (10^9/L) concentration of CD4+ cells in peripheral blood 1-5 days before each therapy cycle during course of therapy (cycle 21 days) through therapy completion, an average of 6 cycles (18 weeks)
Secondary Number of Cytotoxic lymphocytes in peripheral blood of patients Absolute (10^9/L) concentration of CD8+ cells in peripheral blood 1-5 days before each therapy cycle during course of therapy (cycle 21 days) through therapy completion, an average of 6 cycles (18 weeks)
Secondary Number of NK-lymphocytes in peripheral blood of patients Absolute (10^9/L) concentration of CD16+CD56+ cells in peripheral blood 1-5 days before each therapy cycle during course of therapy (cycle 21 days) through therapy completion, an average of 6 cycles (18 weeks)
Secondary Number of CD38+ cells in peripheral blood of patients Absolute (10^9/L) concentration of CD38+ cells in peripheral blood 1-5 days before each therapy cycle during course of therapy (cycle 21 days) through therapy completion, an average of 6 cycles (18 weeks)
Secondary Number of HLA-DR+ cells in peripheral blood of patients Absolute (10^9/L) concentration of HLA-DR+ cells in peripheral blood 1-5 days before each therapy cycle during course of therapy (cycle 21 days) through therapy completion, an average of 6 cycles (18 weeks)
Secondary Number of CD71+ cells in peripheral blood of patients Absolute (10^9/L) concentration of CD71+ cells in peripheral blood 1-5 days before each therapy cycle during course of therapy (cycle 21 days) through therapy completion, an average of 6 cycles (18 weeks)
Secondary Number of B-lymphocytes cells in peripheral blood of patients Absolute (10^9/L) concentration of CD71+ cells in peripheral blood 1-5 days before each therapy cycle during course of therapy (cycle 21 days) through therapy completion, an average of 6 cycles (18 weeks)
Secondary Number of CD25+ cells in peripheral blood of patients Absolute (10^9/L) concentration of CD25+ cells in peripheral blood 1-5 days before each therapy cycle during course of therapy (cycle 21 days) through therapy completion, an average of 6 cycles (18 weeks)
Secondary IgA level IgA (g/L) level in serum 1-5 days before each therapy cycle during course of therapy (cycle 21 days) through therapy completion, an average of 6 cycles (18 weeks)
Secondary IgG level IgG (g/L) level in serum 1-5 days before each therapy cycle during course of therapy (cycle 21 days) through therapy completion, an average of 6 cycles (18 weeks)
Secondary IgM level IgM (g/L) level in serum 1-5 days before each therapy cycle during course of therapy (cycle 21 days) through therapy completion, an average of 6 cycles (18 weeks)
Secondary Spontaneous lymphocytes migration Lymphocytes migration (U) without stimulation 1-5 days before each therapy cycle during course of therapy (cycle 21 days) through therapy completion, an average of 6 cycles (18 weeks)
Secondary Kon-A stimulated migration Lymphocyte migration after in vitro stimulation with Kon A (% inhibition of migration) 1-5 days before each therapy cycle during course of therapy (cycle 21 days) through therapy completion, an average of 6 cycles (18 weeks)
Secondary PGA stimulated migration Lymphocyte migration after in vitro stimulation with PGA (% inhibition of migration) 1-5 days before each therapy cycle during course of therapy (cycle 21 days) through therapy completion, an average of 6 cycles (18 weeks)
Secondary Ingestion rate of monocytes Ingestion rate (%) 1-5 days before each therapy cycle during course of therapy (cycle 21 days) through therapy completion, an average of 6 cycles (18 weeks)
Secondary Ingestion rate of neutrophils Ingestion rate (%) 1-5 days before each therapy cycle during course of therapy (cycle 21 days) through therapy completion, an average of 6 cycles (18 weeks)
Secondary Circulating immune complex level Immune complexes (U) in peripheral blood 1-5 days before each therapy cycle during course of therapy (cycle 21 days) through therapy completion, an average of 6 cycles (18 weeks)
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT03979872 - Risk Information and Skin-cancer Education for Undergraduate Prevention N/A
Recruiting NCT04986748 - Using QPOP to Predict Treatment for Sarcomas and Melanomas
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Recruiting NCT05707286 - Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
Active, not recruiting NCT05470283 - Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma Phase 1
Recruiting NCT05077137 - A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy Phase 1
Active, not recruiting NCT02721459 - XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma Phase 1
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Recruiting NCT05839912 - Excision of Lymph Node Trial (EXCILYNT) (Mel69) N/A
Recruiting NCT04971499 - A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma Phase 1/Phase 2
Recruiting NCT05263453 - HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation Phase 2
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06413680 - A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies Phase 1/Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03348891 - TNF in Melanoma Patients Treated With Immunotherapy N/A
Completed NCT03171064 - Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment Phase 2
Not yet recruiting NCT05539118 - Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma Phase 1/Phase 2
Recruiting NCT05171374 - pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
Withdrawn NCT02854488 - Yervoy Pregnancy Surveillance Study